Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Sage Therapeutics, Inc.

< Previous 1 2 3 Next >
Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics to Present at Bank of America Securities 2022 Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics Announces First Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)
From Sage Therapeutics, Inc.
Via Business Wire
Tickers BIIB SAGE
Sage Therapeutics to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 LUMINARY Study of SAGE-718 in Patients with Mild Cognitive Impairment and Mild Dementia due to Alzheimer’s Disease
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics to Present at 2022 Stifel CNS Days
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics Announces Presentation of Encouraging Results from the Phase 2 PARADIGM Study (Part A) of SAGE-718 in Patients with Mild Cognitive Impairment due to Parkinson’s Disease
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of Care Co-initiated with Placebo in People with MDD
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics’ Third Annual FutureCast Showcases Data from All Three Brain Health Franchises
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress
From Sage Therapeutics, Inc.
Via Business Wire
Tickers BIIB SAGE
Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD
From Sage Therapeutics, Inc.
Via Business Wire
Tickers BIIB SAGE
Sage Therapeutics to Host Sage FutureCast Webcast
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics to Report Third Quarter 2021 Financial Results on Tuesday, November 2, 2021
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022
From Sage Therapeutics, Inc.
Via Business Wire
Tickers BIIB SAGE
Sage Therapeutics and Biogen Announce Consistent Clinically Meaningful Data for Zuranolone Across the LANDSCAPE and NEST Clinical Development Programs Presented at the European College of Neuropsychopharmacology (ECNP) Congress
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics Receives Fast Track Designation for SAGE-718 for the Treatment of Huntington’s Disease
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics to Present at the Morgan Stanley Global Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics to Present at Upcoming August Investor Conferences
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics to Participate in Cowen’s Psychedelics & Novel Mechanisms in Neuropsychiatry Summit
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics to Participate in SVB Leerink’s 3rd Annual CNS Forum
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder
From Sage Therapeutics, Inc.
Via Business Wire
Tickers BIIB SAGE
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.